Critical tumor suppressor function mediated by epithelial mig-6 in endometrial cancer

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5090-5099

  Kim, Tae Hoon ^a   Lee, Dong Kee ^b   Cho, Sung Nam ^b   Orvis, Grant D ^c   Behringer, Richard R ^c   Lydon, John P ^b   Ku, Bon Jeong ^d   McCampbell, Adrienne S ^c   Broaddus, Russell R ^c   Jeong, Jae Wook ^a,e  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Chungnam National University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; MEMBRANE PROTEIN; NOTCH1 RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN BIRC3; UNCLASSIFIED DRUG; WNT7A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EPITHELIUM CELL; FEMALE; GENE FUNCTION; GENE INACTIVATION; GROWTH INHIBITION; HORMONAL REGULATION; HORMONE DEPENDENCE; IMMEDIATE EARLY GENE; MIG 6 GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL; TISSUE SPECIFICITY;

EID: 84882656816     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0241     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987;10:237-46.
3. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
4. Huet-Hudson YM, Andrews GK, Dey SK. Cell type-specific localization of c-myc protein in the mouse uterus: modulation by steroid hormones and analysis of the periimplantation period. Endocrinology 1989;125: 1683-90.
5. Paria BC, Huet-Hudson YM, Dey SK. Blastocyst's state of activity determines the "window" of implantation in the receptive mouse uterus. Proc Natl Acad Sci U S A 1993;90:10159-62.
6. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
7. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 2004;117:132-7.
8. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:1068-73.
9. Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007;22:1953-8.
10. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807.
11. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8.
12. Hoekstra AV, Kim JJ, Keh P, Schink JC. Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med 2008;53:869-73.
13. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med 2010;28:81-90.
14. Kaku T, YoshikawaH, Tsuda H, Sakamoto A, Fukunaga M,Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001;167:39-48.
15. Kim TH, Lee DK, Franco HL, Lydon JP, Jeong JW. ERBB receptor feedback inhibitor 1 regulation of estrogen receptor activity is critical for uterine implantation in mice. Biol Reprod 2010;82:706-13.
16. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, et al. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 2005;24:4540-8.
17. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 2006;12:568-73.
18. Jin N, Gilbert JL, Broaddus RR,Demayo FJ, Jeong JW. Generation of a Mig-6 conditional null allele. Genesis 2007;45:716-21.
19. Jeong JW, Lee KY, Kwak I, White LD, Hilsenbeck SG, Lydon JP, et al. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology 2005;146:3490-505.
20. Jeong JW, Lee HS, Lee KY, White LD, Broaddus RR, Zhang YW, et al. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A 2009;106:8677-82.
21. Kim TH, Franco HL, Jung SY, Qin J, Broaddus RR, Lydon JP, et al. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 2010;29:3770-80.
22. Huang CC, Orvis GD, Wang Y, Behringer RR. Stromal-to-epithelial transition during postpartum endometrial regeneration. PLoS One 2012;7:e44285.
23. Winuthayanon W, Hewitt SC, Orvis GD, Behringer RR, Korach KS. Uterine epithelial estrogen receptor alpha is dispensable for proliferation but essential for complete biological and biochemical responses. Proc Natl Acad Sci U S A 2010;107: 19272-7.
24. Franco HL, Rubel CA, Large MJ, Wetendorf M, Fernandez-Valdivia R, Jeong JW, et al. Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. FASEB J 2012; 26:1218-27.
25. Mitsuhashi Y, Horiuchi A, Miyamoto T, Kashima H, Suzuki A, Shiozawa T. Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology 2012;60:826-37.
26. Afshar Y, Jeong JW, Roqueiro D, DeMayo F, Lydon J, Radtke F, et al. Notch1 mediates uterine stromal differentiation and is critical for complete decidualization in the mouse. FASEB J 2012;26: 282-94.
27. Neubauer NL, Ward EC, Patel P, Lu Z, Lee I, Blok LJ, et al. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis. Horm Cancer 2011; 2:170-81.
28. Kleine W, Maier T, Geyer H, Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990;38:59-65.
29. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Thorpe SM. Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol 1993;12:246-52.
30. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998;69: 220-5.
31. Lee JH, Kim TH, Oh SJ, Yoo JY, Akira S, Ku BJ, et al. Signal transducer and activator of transcription-3 (Stat3) plays a critical role in implantation via progesterone receptor in uterus.FASEB J 2013 Jun 17. [Epub ahead of print].
32. Yin Y, Huang WW, Lin C, Chen H, MacKenzie A, Ma L. Estrogen suppresses uterine epithelial apoptosis by inducing birc1 expression. Mol Endocrinol 2008;22:113-25.
33. Conneely OM, Mulac-Jericevic B, Lydon JP, De Mayo FJ. Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol 2001;179:97-103.
34. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW. Reproductive functions of progesterone receptors. Recent Prog Horm Res 2002;57:339-55.
35. Wang H, Dey SK. Roadmap to embryo implantation: clues from mouse models. Nat Rev Genet 2006;7:185-99.
36. Stovall DW, Halme J. Endometriosis and associated pathology. Curr Opin Obstet Gynecol 1991;3:853-8.
37. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368-78.
38. Dotto GP. Notch tumor suppressor function. Oncogene 2008;27: 5115-23.
39. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011;11:338-51.
40. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008; 27:5124-31.
41. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012;11:109-24.
42. Wang S, Bai L, Lu J, Liu L, Yang CY, Sun H. Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia 2012;17:217-28.
43. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10.
44. Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 2001;54:624-30.
45. Tan J, Paria BC, Dey SK, Das SK. Differential uterine expression of estrogen and progesterone receptors correlates with uterine preparation for implantation and decidualization in the mouse. Endocrinology 1999;140:5310-21.
46. Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004;67: 417-34.
47. Liu T, Ogle TF. Signal transducer and activator of transcription 3 is expressed in the decidualized mesometrium of pregnancy and associates with the progesterone receptor through protein-protein interactions. Biol Reprod 2002;67:114-8.
48. Grosskinsky CM, Halme J. Endometriosis: the host response. Baillieres Clin Obstet Gynaecol 1993;7:701-13.
49. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med 1998; 43:73-83.